The novel approach to treating cancer is gaining traction
Cancer sufferers may soon have a simpler method to fight their pain. According to Australia’s Medlab, the company has successfully completed the first round of clinical trials of a cannabis mouth spray that helps patients mitigate the pain associated with their cancer. This could be a revolutionary method to provide relief to hundreds of thousands of individuals dealing with pain from cancer and, ultimately, other ailments.
Medlab’s NanaBis spray has successfully passed testing designed to determine its safety and tolerability. The spray is meant to be a replacement for opioids in advance cancer pain and could help reverse a trend that has seen a skyrocketing increase in opioid deaths since 1999. As of recent data, more than 30,000 people in the U.S. died from an opioid overdose last year.
Clinical trials typically involved three phases – safety, effectiveness and improvement over existing treatments. With NanaBis having passed the initial trials, the drug was approved by Australia’s Data Safety Monitoring Board (DSMB) to proceed with additional tests.
NanaBis is administered through NanoCelle, a drug delivery platform created by Medlab. The platform delivers NanaBis as tiny particles in a mouth spray, where it is delivered to the buccal membrane, the lining of the cheek. From there, it is absorbed into the bloodstream for distribution as a pain reliever throughout the body.
It’s an innovative solution that shows great promise. Not only can it help provide much-needed pain relief, but it is also capable of being used virtually anywhere, which will give users the comfort of knowing they can treat their cancer without fear of social stigmas.
